AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
AAPL   318.68 (+0.14%)
MSFT   181.19 (-0.12%)
FB   224.68 (-0.35%)
GOOGL   1,422.61 (+0.31%)
AMZN   2,409.47 (+0.35%)
NVDA   342.91 (+1.01%)
CGC   17.59 (-19.02%)
BABA   198.52 (-0.49%)
MU   46.66 (+0.41%)
GE   6.51 (-3.98%)
TSLA   817.27 (+1.42%)
AMD   52.23 (+0.95%)
T   30.61 (-1.45%)
ACB   14.04 (-8.47%)
F   5.64 (-3.59%)
GILD   75.05 (-0.36%)
DIS   114.49 (-1.94%)
NFLX   413.30 (-0.03%)
BAC   24.40 (-1.85%)
BA   144.04 (-3.86%)
Log in

OTCMKTS:ZYXIZynex Stock Price, Forecast & News

$19.42
+0.49 (+2.59 %)
(As of 05/29/2020 12:22 PM ET)
Add
Compare
Today's Range
$19.14
Now: $19.42
$19.99
50-Day Range
$11.93
MA: $16.43
$21.74
52-Week Range
$6.96
Now: $19.42
$22.75
Volume182,188 shs
Average Volume527,129 shs
Market Capitalization$644.61 million
P/E Ratio88.27
Dividend YieldN/A
Beta1.05
Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Read More
Zynex logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZYXI
CUSIPN/A
Phone303-703-4906

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.43 million
Cash Flow$1.08 per share
Book Value$0.15 per share

Profitability

Net Income$7.36 million

Miscellaneous

EmployeesN/A
Market Cap$644.61 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ZYXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.

Zynex (OTCMKTS:ZYXI) Frequently Asked Questions

How has Zynex's stock been impacted by COVID-19 (Coronavirus)?

Zynex's stock was trading at $11.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZYXI shares have increased by 77.0% and is now trading at $19.63. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zynex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zynex.

How were Zynex's earnings last quarter?

Zynex Inc. (OTCMKTS:ZYXI) posted its earnings results on Tuesday, April, 28th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. The company earned $15.23 million during the quarter, compared to analyst estimates of $15.07 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. View Zynex's earnings history.

What guidance has Zynex issued on next quarter's earnings?

Zynex updated its second quarter 2020 After-Hours earnings guidance on Tuesday, April, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.5-18 million, compared to the consensus revenue estimate of $16.95 million.

What price target have analysts set for ZYXI?

3 brokers have issued twelve-month target prices for Zynex's shares. Their forecasts range from $20.00 to $25.50. On average, they anticipate Zynex's share price to reach $22.17 in the next year. This suggests a possible upside of 12.9% from the stock's current price. View analysts' price targets for Zynex.

Has Zynex been receiving favorable news coverage?

Headlines about ZYXI stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynex earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutZynex.

Who are some of Zynex's key competitors?

What other stocks do shareholders of Zynex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include Aurora Cannabis (ACB), FuelCell Energy (FCEL), Pfizer (PFE), AT&T (T), Exxon Mobil (XOM), Aytu Bioscience (AYTU), BioDelivery Sciences International (BDSI), Canopy Growth (CGC), IBM (IBM) and Melinta Therapeutics (MLNT).

Who are Zynex's key executives?

Zynex's management team includes the following people:
  • Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
  • Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
  • Mr. David B. Mogill, VP of Operations
  • Mr. Robert Bird, VP of Marketing
  • Mr. Steve Siefring, Director of Bus. Devel.

What is Zynex's stock symbol?

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

Who are Zynex's major shareholders?

Zynex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.43%), Soleus Capital Management L.P. (1.05%), State Street Corp (1.00%), Calamos Advisors LLC (0.78%), Geode Capital Management LLC (0.75%) and Russell Investments Group Ltd. (0.69%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View institutional ownership trends for Zynex.

Which institutional investors are selling Zynex stock?

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Nuveen Asset Management LLC, WINTON GROUP Ltd, Deutsche Bank AG, BlackRock Inc., UBS Group AG, Bank of New York Mellon Corp, and Engineers Gate Manager LP. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead, and Thomas Sandgaard. View insider buying and selling activity for Zynex.

Which institutional investors are buying Zynex stock?

ZYXI stock was purchased by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., EAM Global Investors LLC, EAM Investors LLC, Advisor Group Holdings Inc., Invesco Ltd., Russell Investments Group Ltd., Redmond Asset Management LLC, and AQR Capital Management LLC. View insider buying and selling activity for Zynex.

How do I buy shares of Zynex?

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zynex's stock price today?

One share of ZYXI stock can currently be purchased for approximately $19.63.

How big of a company is Zynex?

Zynex has a market capitalization of $651.58 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis.

What is Zynex's official website?

The official website for Zynex is www.zynexmed.com.

How can I contact Zynex?

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.